Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on August 12, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026 announced by Monopar Therapeutics.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026 announced by Monopar Therapeutics
- Full financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss widened to $5.3M, or $0.62 per share, from $2.5M, or $0.35 per share
- Cash, equivalents and investments totaled $134.3M, supporting operations through at least December 31, 2027
- ALXN1840 rolling NDA submission initiated, with completion anticipated within the next few months
- Rare Pediatric Disease designation creates potential eligibility for a transferable pediatric Priority Review Voucher upon approval
- R&D spending rose to $4.77M from $1.73M, reflecting accelerated regulatory and development activity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.